{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:38:25Z","timestamp":1791905905364,"version":"4.3.4"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Intermediate-stage (BCLC-B) hepatocellular carcinoma (HCC) beyond the up-to-11 criteria represent a significant therapeutic challenge due to high and heterogeneous tumor burden. This study evaluated the effectiveness and safety of transarterial chemoembolization (TACE) in combination with lenvatinib and tislelizumab for these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort study, patients with unresectable intermediate-stage HCC beyond the up-to-11 criteria were enrolled and divided into TACE monotherapy (T), TACE combined with lenvatinib (TL), or TACE plus lenvatinib and tislelizumab (TLT) group based on the first-line treatment, respectively. The primary endpoint was overall survival (OS). The secondary outcomes included progression-free survival (PFS), tumor response according to RESIST1.1 and modified RECIST, and adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 38, 45, and 66 patients in the T, TL, and TLT groups, respectively. The TLT group exhibited significantly higher ORR and DCR than the other two groups, as assessed by either mRECIST or RECIST 1.1 (all <jats:italic>P<\/jats:italic>&amp;lt;0.05). Median PFS and OS were significantly longer in the TLT group compared with the T group (PFS: 8.5 vs. 4.4 months; OS: 31.5 vs. 18.5 months; all <jats:italic>P<\/jats:italic>&amp;lt;0.001) and TL group (PFS: 8.5 vs. 5.5 months; OS: 31.5 vs. 20.5 months; all <jats:italic>P<\/jats:italic>&amp;lt;0.05). The incidence of TRAEs was slightly higher in the TLT and TL groups than in the T group, while all the toxicities were tolerable. No treatment-related death occurred in all groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>TACE combined with lenvatinib and tislelizumab significantly improved the survival benefit compared with TACE monotherapy and TACE plus lenvatinib in patients with intermediate-stage HCC beyond the up-to-11 criteria, with an acceptable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1430571","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T04:26:55Z","timestamp":1721968015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study"],"prefix":"10.3389","volume":"15","author":[{"given":"Song","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Shuangyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicong","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn","article-title":"Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO)","volume":"10","author":"Lu","year":"2021","journal-title":"Hepatobil Surg Nutr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000485471","article-title":"Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit\/risk assessment","volume":"7","author":"Piscaglia","year":"2018","journal-title":"Liver Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1159\/000508809","article-title":"Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization prior to designing clinical trials","volume":"9","author":"Koroki","year":"2020","journal-title":"Liver Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-014-0298-9","article-title":"Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization","volume":"32","author":"Yamakado","year":"2014","journal-title":"Jpn J Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1329906","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Bolondi","year":"2012","journal-title":"Semin Liver Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000440631","article-title":"Validation of a modified substaging system (Kinki criteria) for patients with intermediate-stage hepatocellular carcinoma","volume":"89","author":"Arizumi","year":"2015","journal-title":"Oncology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12686","article-title":"Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma","volume":"30","author":"Wang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13487","article-title":"New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14194","article-title":"A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma","volume":"39","author":"Lee","year":"2019","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000517393","article-title":"Redefining tumor burden in patients with intermediate-stage hepatocellular carcinoma: the seven-eleven criteria","volume":"10","author":"Hung","year":"2021","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.033","article-title":"LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2142-3","article-title":"Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology","volume":"65","author":"Li","year":"2022","journal-title":"Sci China Life Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2007.06.028","article-title":"A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion\/MR imaging monitoring","volume":"18","author":"Lewandowski","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.3390\/cancers15092609","article-title":"Predictive factors of complete response to transarterial chemoembolization in intermediate stage hepatocellular carcinoma beyond up-to-7 criteria","volume":"15","author":"Saito","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3390\/cancers11081084","article-title":"Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh A liver function: A proof-of-concept study","volume":"11","author":"Kudo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000343875","article-title":"JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan","volume":"3","author":"Kudo","year":"2014","journal-title":"Liver Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000515896","article-title":"Impact of early lenvatinib administration on survival in patients with intermediate-stage hepatocellular carcinoma: A multicenter, inverse probability weighting analysis","volume":"99","author":"Tada","year":"2021","journal-title":"Oncology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.987345","article-title":"Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6353047","DOI":"10.1155\/2023\/6353047","article-title":"Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study","volume":"2023","author":"Wang","year":"2023","journal-title":"J Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA432","article-title":"EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization","volume":"42","author":"Lencioni","year":"2024","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyx180","article-title":"Chemotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"48","author":"Ikeda","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/agt2.552","article-title":"Rhein-based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization","author":"Liang","year":"2024","journal-title":"Aggregate"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202107674","article-title":"Dual tumor microenvironment remodeling by glucose-contained radical copolymer for MRI-guided photoimmunotherapy","volume":"34","author":"Cheng","year":"2022","journal-title":"Adv Mater"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00293","article-title":"Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"11","author":"Zhong","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2023.00099","article-title":"Prognostic performance of the China liver cancer staging system in hepatocellular carcinoma following transarterial chemoembolization","volume":"11","author":"Zhong","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J Hepatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.021","article-title":"Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients","volume":"131","author":"Takayasu","year":"2006","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: Modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1430571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T04:26:59Z","timestamp":1721968019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1430571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2024.1430571"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1430571","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"article-number":"1430571"}}